Molecular Biology of Ovarian Cancer

Genomic and Personalized Medicine, Two-Vol Set

Volumn , Issue , 2009, Pages 913-920

  Pejovic, Tanja ^a   Anderson, Matthew L ^b   Odunsi, Kunle ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70449513746     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-369420-1.00075-5     Document Type: Chapter

References (51)

1. Ahluwalia A., et al. DNA methylation and ovarian cancer. I. Analysis of CpG island hypermethylation in human ovarian cancer using differential methylation hybridization. Gynecol Oncol 2001, 82(2):261-268.
2. An H.J., et al. Comparative proteomics of ovarian epithelial tumors. Journal of proteome research 2006, 5(5):1082-1090.
3. Bandera C.A., Ye B., Mok S.C. New technologies for the identification of markers for early detection of ovarian cancer. Curr Opin Obstet Gynecol 1985, 15(1):51-55.
4. Bell D.R., et al. Detection of P-glycoprotein in ovarian cancer: A molecular marker associated with multidrug resistance. J Clin Oncol 1985, 3(3):311-315.
5. Berchuck A., Kohler M.F., Marks J.R., et al. The p53 tumor suppressor gene frequently is altered in gynecologi cancers. Am J Obstet Gyn 1994, 12:64-69.
6. Buckanovich R.J., Sasaroli D., O'Brien-Jenkins A., Botbyl J., Hammond R., Katsaros D., et al. Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol 2007, 25(7):852-861.
7. Chen T., Triplett J., Dehner B., Hurst B., Colligan B., Pemberton J., et al. Transforming growth factor-beta receptor type I gene is frequently mutated in ovarian carcinomas. Cancer Res 2001, 61(12):4679-4682.
8. Cooper B.C., Ritchie J.M., Broghammer C.L., Coffin J., Sorosky J.I., Buller R.E., et al. Preoperative serum vascular endothelial growth factor levels: Significance in ovarian cancer. Clin Cancer Res 2002, 8:3193-3197.
9. Costello J.F., et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 2000, 24(2):132-138.
10. Devine D.A., et al. Trefoil factor expression in normal and diseased human salivary glands. Human Pathology 2000, 31(4):509-515.
11. Ding W., Tang Q., Espina V., Liotta L.A., Mauger D.T., Mulder K.M. A transforming growth factor-beta receptor-interacting protein frequently mutated in human ovarian cancer. Cancer Res 2005, 65(15):6526-6533.
12. Hu W., Wu W., Nash M.A., Freedman R.S., Kavanagh J.J., Verschraegen C.F. Anomalies of the TGF-beta postreceptor signaling pathway in ovarian cancer cell lines. Anticancer Res 2000, 20(2A):729-733.
13. Do T.V., Symowicz J.C., Berman B.M., Liotta L.A., Petricoin E.F., Stack M.S., Fishman D.A. Lysophosphatic acid down regulates stress fibers and upregulates pro-matrix metalloproteinase-2 activation. Mol Cancer Research 2007, 5(2):121-131.
14. Dressman H.K., Berchuck A., Chan G., Zhai J., Bild A., Sayer R., Cragun J., Clarke J., Whitaker R.S., LiHua L., et al. An integrated genomic-base dapproach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 2007, 25:517-524.
15. Easton D.F., Ford D., Bishop D.T. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995, 56(1):265-271. 15.
16. Esteller M., et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000, 92(7):564-569.
17. Ganesan S., Richardson A.L., Wang Z.C., Iglehart J.D., Miron A., Feunteun J., et al. Abnormalities of the inactive X chromosome are a common feature of BRCA1 mutant and sporadic basal-like breast cancer. Cold Spring Harb Symp Quant Biol 2005, 70:93-97.
18. Garcia-Higuera I., Taniguchi T., Ganesan S., Meyn M.S., Timmers C., Hejna J., et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 2001, 7(2):249-262.
19. Havrilesky L., Alvarez A.A., Whitaker R.S., et al. Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutation. Gynecol Oncol 2001, 83:491-500.
20. Houghtaling S., Timmers C., Noll M., Finegold M.J., Jones S.N., Meyn M.S., et al. Epithelial cancer in Fanconi anemia complementation group D2 (Fancd2) knockout mice [see comment]. Genes Dev 2003, 17(16):2021-2035.
21. Howlett N.G., Taniguchi T., Olson S., Cox B., Waisfisz Q., De Die-Smulders C., et al. Biallelic inactivation of BRCA2 in Fanconi anemia [see comment]. Science 2002, 297(5581):606-609.
22. Jiang H., Feng Y. Hypoxia-inducible factor 1alpha (HIF-1alpha) correlated with tumor growth and apoptosis in ovarian cancer. Int J Gynecol Cancer 2006, 16(Suppl 1):405-412.
23. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002, 3(6):415-428.
24. Kassim S.L., El-Salahy E.M., Fayed S.T., Helal S.A., Helal T., Azzam E.D., et al. Vascular endothelial growth factor and interleukin 8 are associated with poor prognosis in epithelia ovarian cancer patients. Blin Biochem 2004, 37:363-369.
25. Lu L., Katsaros D., Wiley A., Rigault de la Longrais I.A., Risch H.A., Puopolo M., et al. The relationship of insulin-like growth factor-II, insulin-like growth factor binding protein-3, and estrogen receptor-alpha expression to disease progression in epithelial ovarian cancer. Clin Cancer Res 2006, 12(4):1208-1214.
26. Lynch M.A., Nakashima R., Song H., DeGroff V.L., Wang D., Enomoto T., et al. Mutational analysis of the transforming growth factor beta receptor type II gene in human ovarian carcinoma. Cancer Res 1998, 58(19):4227-4232.
27. Macara I.G. Parsing the polarity code. Nat Rev Mol Cell Biol 2004, 5:220-231.
28. Marquez R.T., et al. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clinical cancer research: an official journal of the American Association for Cancer Research 2005, 11(17):6116-6126.
29. Miki Y., Swensen J., Shattuc-Eidens, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266:66-71.
30. Nakai H., Watanabe Y., Ueda H., Hoshiai H. Hypoxia inducible factor 1-alpha expression as a factor predictive of efficacy of taxane/platinum chemotherapy in advanced primary epithelial ovarian cancer. Cancer Lett 2007.
31. Obata K., Morland S.J., Watson R.H., et al. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 1998, 58:2095-2097.
32. Pejovic T., Yates J.E., Liu H.Y., Hays L.E., Akkari Y., Torimaru Y., et al. Cytogenetic instability in ovarian epithelial cells from women at risk of ovarian cancer. Cancer Res 2006, 66(18):9017-9025.
33. Petricoin E.F., et al. Use of proteomic patterns in serum to identify ovarian cancer [see comment]. Lancet 2002, 359(9306):572-577.
34. Rathi A., et al. Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin Cancer Res 2002, 8(11):3324-3331.
35. Ren J., Xiao Y.J., Singh L.S., Zhao X., Zhao Z., Feng L., et al. Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells. Cancer Res 2006, 66:3006-3014.
36. Schiffenbauer, Y.S., Abramovitch, R., Meir, G., Nevo, N., Holzinger, M., Itin, A., Keseht, E. and Neeman, M. (1997). Loss of ovarian function promotes angiogenesis in ovarian carcinomas. Proc. Natl Acad Sci 94(24), 13202-13208.
37. Schlosshauer P.W., Cohen C.J., Penault-Llorca F., Miranda C.R., Bignon Y.J., Dauplat J., et al. Prophylactic oophorectomy: A morphologic and immunohistochemical study. Cancer 2003, 8(12):2599-2606.
38. Sengupta S., Kim K.S., Berk M.P., Oates R., Escobar P., Belinson J., Li W., Lindmer D.J., Williams B., Xu Y. Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion. Oncogene 2006.
39. Shih M., Kurman R.J. Ovarian tumorigenesis: A proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004, 16:1511-1518.
40. Skinner H.D., Zheng J.Z., Fang J., Agani F., Jiang B.H. Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1alpha, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling. J Biol Chem 2004, 279(44):45643-45651.
41. So, J., Navari, J. and Fishman, D.A. (2004). Lysophosphatidic acid enhances epithelial ovarian carcinoma invasion through increased expression of interleukin 8. 95(2), 314-322.
42. Sood A.K. Am J Path 2001, 158(4):1279-1288.
43. Taniguchi T., Tischkowitz M., Ameziane N., Hodgson S.V., Mathew C.G., Joenje H., et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003, 9(5):568-574.
44. Summaries for patients. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility. Ann Intern Med 2005, 143(5):I47. US Preventive Services Task Force recommendations.
45. Wamunyokoli F.W., et al. Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance. Clinical cancer research: an official journal of the American Association for Cancer Research 2006, 12(3):690-700.
46. Wang D., Kanuma T., Mizunuma H., Takama F., Ibuki Y., Wake N., et al. Analysis of specific gene mutations in the transforming growth factor-beta signal transduction pathway in human ovarian cancer. Cancer Res 2006, 60(16):4507-4512.
47. Wei S.H., et al. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res 2002, 8(7):2246-2252.
48. Wooster R., Neuhausen S.L., Mangiou J., et al. Localization of a breast cancer susceptability gene, BRCA2, to chromosome 13q12-13. Science 1994, 265:2088-2090.
49. Xing H., Wang S., Weng D., Chen G., Yang X., Zhou J., Xu G., Lu Y., Ma D. Oncol Rep 2007, 17(1):117-122.
50. Zhang H., et al. Biomarker discovery for ovarian cancer using SELDI-TOF-MS. Gynecol Oncol 2006, 102(1):61-66.
51. Zhu G., Saed G.M., Deppe G., Diamond M.P., Munkarah A.R. Hypoxia upregulates the effects of prostaglandin E2 on ovarian cancer cells. Gynecol Oncol 2004, 94:422-426.